Caribou Biosciences (CRBU) Current Assets (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Current Assets of $122.4 million for Q1 2026, down 43.69% year-over-year from $217.3 million in Q1 2025, and down 15.73% quarter-over-quarter from $145.2 million in Q4 2025.
Caribou Biosciences (CRBU) Current Assets (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Current Assets for 7 consecutive years, with $122.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 43.69% year-over-year to $122.4 million; the TTM figure through Mar 2026 stood at $122.4 million (down 43.69% YoY), while the FY2025 annual figure was $145.2 million, down 33.8% from the prior year.
- Current Assets slipped to $122.4 million in Q1 2026 per CRBU's latest filing, from $145.2 million in the prior quarter.
- Across five years, Current Assets topped out at $368.0 million in Q1 2022 and bottomed at $122.4 million in Q1 2026.
- Historically, Current Assets has averaged $255.9 million across 5 years, with a median of $260.2 million in 2022.
- Annual changes were most pronounced in 2022 — Current Assets jumped 146.86% — and 2026, when it slumped 43.69%.
- Caribou Biosciences' Current Assets stood at $260.2 million in 2022, then surged by 30.2% to $338.8 million in 2023, then plunged by 35.26% to $219.4 million in 2024, then plunged by 33.8% to $145.2 million in 2025, then retreated by 15.73% to $122.4 million in 2026.
- Business Quant data shows CRBU's Current Assets at $122.4 million in Q1 2026, $145.2 million in Q4 2025, and $155.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Caribou Biosciences | 163.09 Mn | 50.78 Mn | - | 116.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 116.60 Mn |
| Mar 31, 2026 | 122.38 Mn |
| Dec 31, 2025 | 145.23 Mn |
| Sep 30, 2025 | 155.51 Mn |
| Jun 30, 2025 | 192.51 Mn |
| Mar 31, 2025 | 217.32 Mn |
| Dec 31, 2024 | 219.38 Mn |
| Sep 30, 2024 | 237.43 Mn |
| Jun 30, 2024 | 270.88 Mn |
| Mar 31, 2024 | 304.51 Mn |
| Dec 31, 2023 | 338.84 Mn |
| Sep 30, 2023 | 350.69 Mn |
| Jun 30, 2023 | 268.54 Mn |
| Mar 31, 2023 | 239.49 Mn |
| Dec 31, 2022 | 260.25 Mn |
| Sep 30, 2022 | 306.92 Mn |
| Jun 30, 2022 | 352.93 Mn |
| Mar 31, 2022 | 368.01 Mn |
| Dec 31, 2021 | 391.19 Mn |
| Sep 30, 2021 | 449.05 Mn |